Skip to main content
. 2020 Feb 28;11(2):155. doi: 10.1038/s41419-020-2338-y

Table 2.

Description of the study population between colorectal cancer patients with LDLRAD4 low and high expression.

Variables, N (%) LDLRAD4 expression p-value
Low (N = 221) High (N = 55)
Gender 0.555
Male 131 (59.3) 35 (63.6)
Female 90 (40.7) 20 (36.4)
Age 0.027
<60 129 (58.4) 41 (74.5)
≥60 92 (41.6) 14 (25.5)
TNM stage 0.139
I 18 (8.1) 3 (5.4)
II 66 (29.9) 15 (27.3)
III 99 (44.8) 33 (60.0)
IV 38 (17.2) 4 (7.3)
T stage 0.461
T2 37 (16.7) 6 (10.9)
T3 41 (18.6) 13 (23.6)
T4 143 (64.7) 36 (65.5)
N stage 0.881
N0 98 (44.3) 22 (40.0)
N1 65 (29.5) 18 (32.7)
N2 58 (26.2) 15 (27.3)
M stage 0.067
M0 183 (82.8) 51 (92.7)
M1 38 (17.2) 4 (7.3)
Tumor location 0.489
Colon 101 (45.7) 28 (50.9)
Rectum 120 (54.3) 27 (49.1)
Grade 0.728
Well/moderate 177 (80.1) 43 (78.2)
Poor 44 (19.9) 12 (21.8)
Histological type 0.511
Adenocarcinoma 208 (94.1) 53 (96.4)
Mucinous 13 (5.9) 2 (3.6)
LNH 0.171
<12 69 (31.2) 12 (21.8)
≥12 152 (68.8) 43 (78.2)
Perineural invasion 0.934
Negative 185 (84.1) 46 (83.6)
Positive 35 (15.9) 9 (16.4)
Vascular invasion 0.954
Negative 148 (67.0) 36 (65.5)
Positive 70 (31.7) 18 (32.7)
Unknown 3 (1.3) 1 (1.8)
Pre-treatment CEA 0.623
Negative 133 (60.2) 37 (67.3)
Positive 79 (35.7) 16 (29.1)
Unknown 9 (4.1) 2 (3.6)
Adjuvant chemotherapy 0.026
No 41 (18.5) 8 (14.6)
Yes 144 (65.2) 45 (81.8)
Unknown 36 (16.3) 2 (3.6)
MSI status/MMR status 0.004
MSS/MMR-proficient 150 (67.9) 26 (47.3)
MSI/MMR-deficient 71 (32.1) 29 (52.7)

LNH number of lymph nodes harvested, CEA carcinoembryonic antigen, MSI microsatellite instability, MSS microsatellite stability, MMR mismatch repair.